Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 8Neoplasms 4Neoplasm Metastasis 4Endometrial Neoplasms 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Prostatic Diseases 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Male Urogenital Diseases 1Leukemia, Myeloid, Acute 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Genital Diseases, Male 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Advanced Cancer 1

Interventions

Cisplatin 252Radiotherapy 176Cetuximab 144pembrolizumab 120Docetaxel 96Fluorouracil 92Carboplatin 80Paclitaxel 77Radiotherapy, Intensity-Modulated 69Nivolumab 37Radiation 30Drug Therapy 30Erlotinib Hydrochloride 26Gemcitabine 25Gefitinib 21Cyclophosphamide 21Surveys and Questionnaires 20Surgical Procedures, Operative 19Standard of Care 19Pemetrexed 19durvalumab 18Magnetic Resonance Spectroscopy 17Capecitabine 17Radiosurgery 16Celecoxib 16atezolizumab 15Filgrastim 15Amifostine 15Low-Level Light Therapy 14Everolimus 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Head and Neck Neoplasms × gedatolisib × Clear all
NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Suspended
75 enrolled
GastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡